While childhood cancers are thankfully rare, neuroblastoma—which accounts for 6-10% of all cases in children under 15 and tragically causes 15% of pediatric cancer deaths—strikes with a heartbreakingly specific pattern, with 90% of its nearly 800 annual U.S. cases diagnosed before a child's fifth birthday.
Key Takeaways
- Neuroblastoma accounts for about 6-10% of all childhood cancers in children younger than 15 years.
- In the United States, approximately 700-800 new cases of neuroblastoma are diagnosed annually in children.
- The median age at diagnosis for neuroblastoma is 19 months, with 90% of cases occurring in children under 5 years old.
- ALK gene mutations are found in 6-10% of sporadic neuroblastomas.
- MYCN amplification occurs in 20% of all neuroblastoma cases and is associated with poor prognosis.
- PHOX2B germline mutations cause 25% of familial neuroblastomas.
- Urine catecholamine metabolites (VMA/HVA) elevated in 90-95% of cases.
- MIBG scan avidity in 90% of neuroblastomas for staging.
- INSS stage 4S has special prognosis, seen in 10% of cases under 1 year.
- Over 50% of high-risk neuroblastoma patients receive chemotherapy as first-line treatment.
- Surgery alone cures 80-90% of low-risk localized neuroblastomas.
- High-dose chemotherapy with autologous stem cell transplant in 40% high-risk cases.
- 5-year overall survival for low-risk neuroblastoma is 95-100%.
- High-risk neuroblastoma has 5-year OS of 50-55% with current therapies.
- Infants under 12 months with stage 4 have 80-90% survival.
Neuroblastoma is a childhood cancer with high survival rates if caught early.
Diagnosis and Staging
1Urine catecholamine metabolites (VMA/HVA) elevated in 90-95% of cases.
Verified2MIBG scan avidity in 90% of neuroblastomas for staging.
Verified3INSS stage 4S has special prognosis, seen in 10% of cases under 1 year.
Verified4Bone marrow involvement in 70% of metastatic disease at diagnosis.
Directional5MRI is preferred for primary tumor imaging in 95% of abdominal cases.
Single source6INRGSS staging uses image-defined risk factors (IDRF) in 60% for surgical planning.
Verified7LDH >1400 IU/L indicates high-risk disease in 75% of cases.
Verified8Ferritin >142 ng/mL is a poor prognostic marker in 70% of patients.
Verified9Bone cortex metastases detected by MRI in 30% more cases than skeletal survey.
Directional10123I-MIBG uptake score correlates with response in 85% of scans.
Single source11Histology shows undifferentiated tumors in 25% of high-risk cases.
Verified12Shimada age-linked classification favorable in 60% under 18 months.
Verified13PET/CT with FDG used in 10% of MIBG-negative tumors.
Verified14Liver metastases in stage 4S in 80-90% of cases.
Directional15Neuron-specific enolase (NSE) elevated in 80% at diagnosis.
Single source16Cytogenetic analysis reveals near-triploidy in 25% favorable cases.
Verified17Urine HVA/VMA ratio >1 poor prognosis in 65% infants.
Verified18Bilateral bone marrow biopsies positive in 50% metastatic disease.
Verified19Prenatal ultrasound detects 5-10% of congenital neuroblastomas.
Directional20CT scan shows calcifications in 85% of primary tumors.
Single source21INRG-A staging: L1 (localized) 20%, L2 25%, M 55%.
Verified22Opsoclonus-myoclonus syndrome (dancing eye) in 2-3% of cases.
Verified23Ganglioneuroblastoma intermediate in 15-20% histology.
Verified24Flow cytometry for immunophenotyping in 40% research cases.
Directional2568Ga-DOTATATE PET emerging for somatostatin receptor imaging in 15% cases.
Single source26Stage 1 INSS: complete gross excision, 5% of cases.
Verified27Multimodality imaging changes staging in 30% of cases.
Verified28Serum chromogranin A elevated in 70% neuroblastoma patients.
VerifiedDiagnosis and Staging Interpretation
While neuroblastoma is a master of disguise with its 90% detection rate through urine tests, its secrets are unraveled by a suite of modern tools, from MRI's superior imaging to genetic markers, which together paint a stark portrait of risk and guide the battle plan for each unique patient.
Incidence and Epidemiology
1Neuroblastoma accounts for about 6-10% of all childhood cancers in children younger than 15 years.
Verified2In the United States, approximately 700-800 new cases of neuroblastoma are diagnosed annually in children.
Verified3The median age at diagnosis for neuroblastoma is 19 months, with 90% of cases occurring in children under 5 years old.
Verified4Incidence rate of neuroblastoma is about 10.2 cases per million children under 15 years in the US.
Directional5Neuroblastoma represents 15% of all pediatric cancer deaths despite comprising only 8% of cases.
Single source6Global incidence of neuroblastoma is estimated at 10.5 per million children aged 0-14 years.
Verified7In Europe, around 1,400 new cases are diagnosed yearly in children under 15.
Verified8Boys have a slightly higher incidence of neuroblastoma than girls (male:female ratio 1.1:1).
Verified9Neuroblastoma incidence peaks in the first year of life at 50-60 cases per million.
Directional10In Australia, neuroblastoma incidence is 8.2 per million children under 5 years.
Single source11About 88% of neuroblastomas are diagnosed before age 5, with 34% under 1 year.
Verified12African American children have a higher incidence rate of 12.4 per million vs. 9.5 for whites.
Verified13Neuroblastoma comprises 11% of cancers in infants under 1 year.
Verified14Annual incidence in the UK is 1 in 7000-10000 live births.
Directional15In Japan, neuroblastoma screening programs detect 40-50 cases per year prenatally.
Single source16SEER data shows 5-year limited-duration prevalence of 2,900 cases in US children.
Verified17Neuroblastoma is rare after age 10, with less than 2% of cases in adolescents.
Verified18Hispanic children have an incidence of 11.3 per million for neuroblastoma.
Verified19In Canada, 120-140 new cases diagnosed annually in children under 15.
Directional20Familial neuroblastoma accounts for 1-2% of all cases.
Single source21Neuroblastoma arises from neural crest cells, most commonly in the adrenal medulla (35-50% of cases).
Verified2220-25% of neuroblastomas originate in the abdomen outside the adrenal gland.
Verified23Thoracic neuroblastoma accounts for 15-20% of cases.
Verified24Cervical neuroblastoma is very rare, comprising less than 5% of cases.
Directional25Pelvic neuroblastoma occurs in 2-5% of patients.
Single source2665% of neuroblastomas present with abdominal mass at diagnosis.
Verified27Metastatic disease is present at diagnosis in 50-60% of cases.
Verified28In low-income countries, neuroblastoma incidence is underreported, estimated 20% lower.
Verified29Neuroblastoma survival has improved from 54% in 1975 to 81% in 2018 in the US.
Directional30Approximately 1% of neuroblastomas are congenital, detected prenatally.
Single sourceIncidence and Epidemiology Interpretation
Neuroblastoma is a sinister shape-shifter of childhood cancer, arriving almost exclusively under the cover of toddlerhood, disproportionately claiming lives despite its rarity, and cleverly hiding in plain sight until it’s often already on the march.
Risk Factors and Genetics
1ALK gene mutations are found in 6-10% of sporadic neuroblastomas.
Verified2MYCN amplification occurs in 20% of all neuroblastoma cases and is associated with poor prognosis.
Verified3PHOX2B germline mutations cause 25% of familial neuroblastomas.
Verified4Children with Beckwith-Wiedemann syndrome have a 20-fold increased risk of neuroblastoma.
Directional5Hirschsprung disease is associated with neuroblastoma in 2-5% of familial cases.
Single source6TrkA (NTRK1) expression is favorable in 80% of low-stage neuroblastomas.
Verified71p36 deletion/LOH is present in 25-35% of high-risk neuroblastomas.
Verified8Germline BARD1 mutations increase neuroblastoma risk by 10-fold.
Verified9Hyperdiploidy (DNA index >1) is favorable in 75% of infants with neuroblastoma.
Directional10TP53 mutations occur in less than 2% of primary neuroblastomas but 10-20% in relapses.
Single source11Familial neuroblastoma inheritance is autosomal dominant with 20-50% penetrance for PHOX2B.
Verified12ALK F1174L mutation is the most common activating mutation, seen in 3-5% of cases.
Verified1311q loss of heterozygosity occurs in 40% of non-MYCN amplified tumors.
Verified14Congenital central hypoventilation syndrome (CCHS) due to PHOX2B has 50% neuroblastoma risk.
Directional15Aneuploidy is protective, with 85% event-free survival in hyperdiploid cases.
Single source16LIN28B overexpression correlates with MYCN amplification in 90% of cases.
Verified17Germline KIF1B mutations in 1-2% of familial cases.
Verified18TrkB expression is high in 60% of high-risk neuroblastomas.
Verified1917q gain is the most common chromosomal aberration, in 70-80% of cases.
Directional20No strong environmental risk factors identified; maternal alcohol use weakly associated (OR 1.5).
Single source21Prenatal vitamin use may reduce risk by 30-40% in some studies.
Verified22Oligohydramnios is associated with 2-fold increased risk in prenatal cases.
Verified23Maternal cocaine use increases neuroblastoma risk (OR 3.7).
Verified24International Neuroblastoma Risk Group (INRG) classification uses genetic markers for 80% risk stratification.
Directional25Whole-genome sequencing reveals structural variants in 90% of high-risk tumors.
Single source26ATRX mutations in 5-10% of older children with neuroblastoma.
Verified273p deletion in 15-20% of cases, associated with poor outcome.
VerifiedRisk Factors and Genetics Interpretation
Neuroblastoma is a genetic gauntlet where a few favorable genes can feel like winning the lottery, but an unlucky draw from a deck stacked with MYCN amplifications, ALK mutations, and chromosomal chaos often dictates a brutally difficult course.
Survival and Prognosis
15-year overall survival for low-risk neuroblastoma is 95-100%.
Verified2High-risk neuroblastoma has 5-year OS of 50-55% with current therapies.
Verified3Infants under 12 months with stage 4 have 80-90% survival.
Verified4MYCN amplified tumors have 20-30% 5-year EFS vs. 70% non-amplified.
Directional5Stage 4S spontaneous regression in 80% of cases without treatment.
Single source6Relapsed neuroblastoma 5-year OS <10% for high-risk.
Verified7Favorable Shimada histology improves OS by 40%.
Verified8INRG high-risk group 5-year OS 50%, intermediate 85-90%.
Verified9Bone marrow remission predicts 70% long-term survival.
Directional10Age >18 months with metastatic disease OS 40%.
Single source1111q LOH without MYCN amp has 70% 5-year EFS.
Verified12Very low-risk observation group 98% EFS at 3 years.
Verified13Central nervous system metastases reduce OS to 15-20%.
Verified14Post-transplant isotretinoin improves EFS by 15% to 46%.
Directional15Stage 1 disease 5-year OS 99%.
Single source16Hyperdiploid low MKI tumors 95% survival.
Verified17Dinutuximab adds 20% OS benefit (55% vs 35%).
Verified18Prenatally diagnosed have 95% survival rate.
Verified19INSS stage 4 age <1 year OS 85%.
Directional20Anaplastic lymphoma kinase inhibitors improve PFS by 50% in mutants.
Single source21Mature ganglioneuroma differentiation leads to 100% survival.
Verified22Event-free survival plateau at 3 years indicates cure in 75%.
Verified23Liver failure in stage 4S mortality 10-15%.
Verified24International cohort 10-year OS 79% overall.
Directional25Low-risk biopsy-only 97% EFS.
Single source26MYCN non-amp stage 4 >72 months OS 60%.
Verified27Long-term cardiac toxicity in 20% survivors from anthracyclines.
Verified2830-year OS improved to 80% from 40% historically.
VerifiedSurvival and Prognosis Interpretation
Neuroblastoma is a tale of two diseases: one where a simple watchful eye yields near-perfect survival, and another where even our most aggressive therapies feel like a desperate gamble against grim odds.
Treatment Modalities
1Over 50% of high-risk neuroblastoma patients receive chemotherapy as first-line treatment.
Verified2Surgery alone cures 80-90% of low-risk localized neuroblastomas.
Verified3High-dose chemotherapy with autologous stem cell transplant in 40% high-risk cases.
Verified4Radiation therapy used in 25% of intermediate-risk patients post-surgery.
Directional5MIBG therapy effective in 30-40% of relapsed/refractory cases.
Single source6Cisplatin, doxorubicin, etoposide, cyclophosphamide in N5/N6 induction regimens for 70% high-risk.
Verified7Dinutuximab beta immunotherapy improves EFS by 20% in HR-NBL1 trial.
Verified8Gross total resection achieved in 50% of high-risk abdominal tumors.
Verified9Topotecan + cyclophosphamide for refractory disease in 60% second-line.
Directional1013-cis-retinoic acid (isotretinoin) consolidation in 90% high-risk post-transplant.
Single source11CAR-T cell therapy in trials shows 20-30% response in ALK-mutated.
Verified12Proton beam radiotherapy reduces dose to organs in 40% thoracic cases.
Verified13Irinotecan/temozolomide oral regimen used in 50% maintenance therapy.
Verified14GD2-targeted vaccine trials ongoing for 15% minimal residual disease.
Directional15Nephrectomy required in 20% adrenal cases with vascular encasement.
Single source16Busulfan/melphalan myeloablative regimen in 70% European protocols.
Verified17Lorlatinib ALK inhibitor phase 2 response 30% in relapsed ALK-mutant.
Verified18Focal radiation dose 21.6 Gy in 80% INSS stage 3.
Verified19Observation alone for asymptomatic stage 4S in 25% cases.
Directional20Anti-GD2 monoclonal antibody (naxitamab) FDA approved, ORR 50% relapsed.
Single source21Tandem transplant improves OS by 10-15% in high-risk COG trials.
Verified22Anlotinib anti-angiogenic in trials, PFS 6 months in 40% refractory.
Verified23Thoracotomy for thoracic resection in 15% cases.
Verified24Enteric-coated isotretinoin reduces GI toxicity in 85% patients.
Directional25177Lu-DOTATATE PRRT in 20% somatostatin-positive relapsed.
Single source26Dose-intensive induction achieves PR/CR in 70-80% high-risk.
VerifiedTreatment Modalities Interpretation
Neuroblastoma treatment is a brutal arithmetic where we must strategically assemble every weapon—from surgery and chemotherapy to targeted therapies and immunotherapy—to win a war that starts with the starkly different equations of low-risk and high-risk disease.
Sources & References
- Reference 1CANCERcancer.govVisit source
- Reference 2SEERseer.cancer.govVisit source
- Reference 3NCBIncbi.nlm.nih.govVisit source
- Reference 4PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 5IARCiarc.who.intVisit source
- Reference 6ENCEPPencepp.euVisit source
- Reference 7AIHWaihw.gov.auVisit source
- Reference 8CANCERcancer.orgVisit source
- Reference 9CCLGcclg.org.ukVisit source
- Reference 10CANCERcancer.caVisit source